Breast Cancer PharmacoTherapeutic Market


Published on

The study includes detailed discussions on the impact of critical factors, such as genericization, patent cliffs, drug shortages, reimbursement, predictive testing and personalized medicine, to help current and contemplative drug sponsors navigate the breast cancer pharmacotherapeutic market.

  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Breast Cancer PharmacoTherapeutic Market

  1. 1. Breast Cancer Therapies MarketsBreast cancer therapies are entering a new era as game-changers emerge for each of the majorbreast cancer patient populations. New market entrants must possess drug profiles and a savvyclinical development program to overcome such barriers to entry as a stringent regulatoryenvironment and the incursion of cost containment within oncology. This TriMark Publicationsreport provides comprehensive information on major and minor shapers of the breast cancerdrug treatment landscape. The study includes detailed discussions on the impact of criticalfactors, such as genericization, patent cliffs, drug shortages, reimbursement, predictive testingand personalized medicine, to help current and contemplative drug sponsors navigate thebreast cancer pharmacotherapeutic market. Moreover, this report contains a detailed analysisof each of the seven main modalities of breast cancer therapies, i.e., hormone therapy, surgery,radiation, molecular targeted therapy, chemotherapy, hormone treatment and targeted drugtherapy. Additionally, this study examines prescribing trends and the arrival of the firstbiosimilar agents and electronic records in post-marketing surveillance.Get your copy @ Details:Published: November 2012No. of Pages: 271Price: Single User License – US$3400 Corporate User License – US$6800Table of Contents1. Overview 91.1 About This Report 91.2 Scope of This Report 91.3 Objectives 91.4 Methodology 101.5 Drugs Covered in This Report 111.6 Summary of Major Findings 13
  2. 2. 2. About Breast Cancer 162.1 Tumorigenesis 162.2 Classification of Breast Cancer 172.3 Risk Factors of Breast Cancer 172.3.1 Gender, Age and Reproductive Status 182.3.2 Genetic Mutation and Family History 192.3.3 Environmental Factors 192.3.4 Breast Density 202.4 The Various Options for Treating Breast Cancer 202.4.1 Prevention of Breast Cancer 202.4.2 Chemoprevention 202.4.3 Prophylactic Surgery 212.4.4 Radiation Therapy 212.4.5 Systemic Therapy 212.4.6 Targeted Therapy 212.4.7 Chemotherapy 222.4.8 Hormone Therapy 223. Global and Regional Data on Breast Cancer 233.1 Global Breast Cancer Statistics, 2012 233.2 Breast Cancer in the U.S. 283.2.1 U.S. Breast Cancer Statistics at a Glance 283.2.2 Breast Cancer Occurrence in the U.S. 293.2.3 Geographic Differences in Breast Cancer Rates in the U.S. 293.2.4 Breast Cancer Mortality Rate in the U.S. 313.2.5 Breast Cancer in the U.S. by Age 323.2.6 Changing Trends in In Situ Breast Cancer 323.2.7 Changing Trends in Invasive Breast Cancer in the U.S. 333.2.8 Breast Cancer in the U.S. by Tumor Size 343.2.9 Breast Cancer by Age and Ethnicity in the U.S. 363.2.10 U.S.: Early Detection of Breast Cancer 373.2.10.1 Breast Cancer Screening in the U.S. 373.3 Breast Cancer in Canada 383.4 Breast Cancer Screening, Survival and Mortality in OECD Countries 393.5 Breast Cancer in U.K. 433.5.1 Female Breast Cancer by Age in U.K. 433.6 Breast Cancer in Australia 443.7 Breast Cancer in China 453.7.1 Treatment Patterns in China for Breast Cancer 463.8 Burden of Breast Cancer in India 493.9 Overview of Breast Cancer Incidence in Seven Major Markets 50
  3. 3. 4. Pharmaceutical Drugs Used in Breast Cancer Treatment 514.1 Selected Classes of Chemotherapies 514.1.1 Chemotherapies Available as Generics 524.1.2 Branded Chemotherapies 544.2 Hormone Treatments 564.3 Targeted Drug Therapy 585. Game Changers for Her2+ Breast Cancer for the Current Decade 645.1 Targeted Her2 Therapies in their Prime 645.2 About Her2+ Carcinoma 645.3 Molecular Targeted Agents 655.3.1 Herceptin 665.3.1.1 Mechanism of Action of Herceptin 665.3.1.2 Drug Profile of Herceptin 685.3.1.3 Herceptin Resistance 725.3.1.4 Herceptin Product Positioning 735.3.1.5 Herceptin in the Adjuvant Setting 745.3.1.6 Herceptin Biosimilars in Development 745.3.1.7 Herceptin SC Reformulation 755.4 Predictive Testing for Her2+ Breast Cancer 755.5 New and Emerging Her2 Targeted Options 775.5.1 Pertuzumab 785.5.2 T-DM: Chemotherapy with Fewer Side Effects to Win the Patients 825.6 Roche’ s Her2 Portfolio and Oncology Pipeline 865.7 Data Prediction of Tykerb Utility after Failure of Herceptin Monotherapy 885.7.1 ALTTO and NEO-ALTTO: Drive Her2+ Tumors into Adjuvant Setting 945.7.2 TEACH Trial 975.7.3 Tykerb Product Positioning 985.7.4 GSK’ s Oncology Pipeline 985.8 Emerging Diagnostics to Aid Her2 Targeted Drug Selection 995.9 The More Distant Future of Her2 Targeted Therapy 995.9.1 Afinitor 995.9.2 Afatinib 995.9.3 Neratinib 1006. Game Changers for Estrogen Receptor Positive Breast Cancer for Current Decade 1016.1 About ER+ Breast Cancer 1016.1.1 Standard of Care for the Treatment of ER+ Breast Cancer 1026.2 Adjuvant Chemotherapy in ER+ Breast Cancer 1036.3 Adjuvant Hormone Therapy in ER+ Breast Cancer 1046.4 Afinitor Expected to be a Game Changer in ER+ Breast Cancer 1056.4.1 mTOR/PI3k Resistance 110
  4. 4. 6.5 Novartis’ Oncology Pipeline 1106.6 Biphosphonates Shown to Reduce Bone Metastases 1127. Triple Negative Breast Cancer (TNBC) 1157.1 Avastin 1157.2 Angiogenesis Drugs in Development 1197.3 PARP Inhibitors 1208. Advances in Chemotherapy 1248.1 Standard of Care for Chemotherapy 1248.1.1 Physician Preference 1278.2 New and Emerging Chemotherapies 1278.3 Using Existing Chemotherapies in Novel Ways 1298.4 Chemotherapies Reformulations 1308.5 Chemotherapies and Drug Shortage Crisis 1308.6 Future Trends: Tailoring Care 1318.7 Elderly Patients 1318.8 Adjuvant Chemotherapy in ER+ Breast Cancer 1318.9 Adjuvant Chemotherapy in Her2+ Breast Cancer 1329. Biomarkers, Molecular Diagnostics and Personalized Medicine in Breast Cancer Treatment1339.1 Overview of Markers and Diagnostics as Game Changers in Breast Cancer Treatment 1339.2 Personalized Medicine: Applied Biomarkers and Companion Diagnostics 1339.3 Multigene Diagnostic Tests 1379.4 Biomarkers: Drug Tolerability and Toxicity 1399.5 Personalized Medicine and Companion Diagnostic Tests in Breast Cancer 1419.6 Her2 and Herceptin 1439.7 Bayer’ s Advia Centaur Her2 Assay 1459.8 Epidermal Growth Factor Receptor Companions 1459.9 Companies Marketing Her2 Assays 1469.9.1 Myriad’ s BRCA Companion Diagnostics Testing for BioMarin’ s PARP Inhibitor BMN 6731469.10 Biomarkers as Endpoints in Drug Discovery 1479.11 Risks and Uncertainties of Companion Diagnostics 1499.12 Biomarkers, Companion Diagnostics and Regulatory Environment 15110. Drug Development for the Treatment of Breast Cancer 15310.1 Targeted Drugs of the PI3k/mTOR Pathway 15410.2 Her2 Targeted Agents 15610.2.1 Neratinib 15610.2.2 Afatinib 15710.3 VEGF Modulators 158
  5. 5. 10.4 Biologics 15910.5 Vaccines 15910.6 Overview of Safety Profiles of Pipeline Agents 16111. Regulatory Trends: How Authorities May Change the Game 16411.1 Introduction to Regulatory Trends 16411.2 Case Study Avastin: Regulators Look to Overall Survivor Data 16511.3 Case Study: T-DMI and Unmet Need 16711.4 Case Study: Halaven and Trial Design 16811.5 Postmarketing Surveillance 16811.6 Regulators Look Towards Longer Term Outcomes 16911.7 Regulatory Trends for Combination Therapies 16911.8 Austerity Measures 17011.9 Reimbursement 17111.10 U.S. Healthcare Reform and its Potential Impact on Regulation 17111.11 New PDUFA V Recommendations 17311.12 Generics and Drug Shortages 17311.13 Biomarker, Companion Diagnostics and the Regulatory Pathway 17511.13.1 Regulatory Perspectives on Pharmacogenomics and Biomarker Validation 17511.13.2 Role of Governmental Agencies in Driving the Adoption of Companion Diagnostics 17511.13.3 Role of Insurance Industry in Driving Adoption of Pharmacogenomics 17611.13.4 Role of Pharma Industry in Driving Adoption of Pharmacogenomics 17611.13.5 FDA Guidance Document on Co-Development 17611.13.6 Role of Diagnostic Industry in Driving the Adoption of Pharmacogenomics 17611.14 2012 Regulatory Guidance for Biosimilars 17711.15 Off-Label Use and Good Publication Practices 17811.16 The Future Regulatory Environment for Oncology 17812. Breast Cancer Therapies: Market Analysis 18012.1 Growth in Breast Cancer Drug Market and the New Entrants 18012.1.1 Market for Her2+ Drugs 18112.1.2 Global Market for Breast Cancer Hormonal Therapies 18212.1.3 Declining Revenue for Aromatase Inhibitors 18312.1.4 Market for Targeted Therapy in Breast Cancer 18412.1.5 Shortage of Chemotherapy Drugs 18512.2 Breast Cancer Market in the U.S. 18612.2.1 Growth in Inpatient Breast Cancer Services in the U.S. 18612.2.2 Outpatient Breast Cancer Services in the U.S. 18712.2.3 Chemotherapy Market in the U.S. 18812.2.4 Number of Chemotherapy Patients with Breast Cancer in the U.S. 18912.2.5 Number of Breast Cancer Surgeries in the U.S. 19012.2.6 U.S. Market for Conventional Breast Cancer Treatments 190
  6. 6. 12.2.7 U.S. Market for Standard Imaging Procedures in Breast Cancer 19112.2.8 U.S. Market for Advanced Breast Imaging Procedures 193Appendix 1: Breast Cancer Drug Therapies: Marketed and Development 195Appendix 2: A Woman’ s Guide to Breast Cancer 200Appendix 2.1: Breast Biopsy 200Appendix 2.2: Staging of Breast Cancer 201Appendix 2.3: Treatment Options 203Appendix 3: Cancer Treatment and Survivorship 208Appendix 3.1: Female Breast Cancer 210Appendix 3.1.1: Treatment and Survival After Breast Cancer 211Appendix 3.1.2: Special Concerns of Breast Cancer Survivors 212Appendix 3.2: Childhood Cancer 213Appendix 3.2.1: Treatment and Survival for Childhood Cancer 213Appendix 3.3: Colon and Rectum Cancer 214Appendix 3.3.1: Treatment and Survival for Colon and Rectum Cancer Patients 215Explore more reports on Pharmaceutical Market @, Dallas North - Dominion Plaza,17304, Preston Road,Suite 800, Dallas 75252.+ 1 888 391 5441sales@reportsandreports.comConnect With Us: